421 related articles for article (PubMed ID: 21252717)
41. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
42. A gene signature combining the tissue expression of three angiogenic factors is a prognostic marker in early-stage non-small cell lung cancer.
Sanmartín E; Sirera R; Usó M; Blasco A; Gallach S; Figueroa S; Martínez N; Hernando C; Honguero A; Martorell M; Guijarro R; Rosell R; Jantus-Lewintre E; Camps C
Ann Surg Oncol; 2014 Feb; 21(2):612-20. PubMed ID: 24145997
[TBL] [Abstract][Full Text] [Related]
43. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
44. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival.
Li Y; Krowka MJ; Qi Y; Katzmann JA; Song Y; Li Y; Mandrekar SJ; Yang P
J Thorac Oncol; 2011 Feb; 6(2):291-5. PubMed ID: 21173712
[TBL] [Abstract][Full Text] [Related]
45. Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy.
Bortolin MT; Tedeschi R; Bidoli E; Furlan C; Basaglia G; Minatel E; Gobitti C; Franchin G; Trovò M; De Paoli P
Biomarkers; 2015; 20(6-7):422-8. PubMed ID: 26526078
[TBL] [Abstract][Full Text] [Related]
46. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
[TBL] [Abstract][Full Text] [Related]
48. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
[TBL] [Abstract][Full Text] [Related]
49. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
[TBL] [Abstract][Full Text] [Related]
50. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis.
Takanami I
Oncol Rep; 2004 Oct; 12(4):849-53. PubMed ID: 15375511
[TBL] [Abstract][Full Text] [Related]
52. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M
Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797
[TBL] [Abstract][Full Text] [Related]
53. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
Lin CC; Hsu HH; Sun CT; Shih JY; Lin ZZ; Yu CJ; Chen GG; Hsin MK; Lam KC; Leung L; Yang CH; Mok T
J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634
[TBL] [Abstract][Full Text] [Related]
55. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
56. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
57. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
[TBL] [Abstract][Full Text] [Related]
58. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer.
Hara H; Yamashita K; Shinada J; Yoshimura H; Kameya T
Lung Cancer; 2001 Nov; 34(2):219-26. PubMed ID: 11679180
[TBL] [Abstract][Full Text] [Related]
60. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group.
Tanriverdi O; Avci N; Oktay E; Kalemci S; Pilanci KN; Cokmert S; Menekse S; Kocar M; Sen CA; Akman T; Ordu C; Goksel G; Meydan N; Barutca S
Asian Pac J Cancer Prev; 2015; 16(14):5971-6. PubMed ID: 26320482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
